Drugs / HPG1860
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04480697 | Sep 2019 → Nov 2020 | — | Hepagene (Shanghai) Co., Ltd. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05338034 | Nov 2021 → Feb 2023 | metabolic dysfunction-associated steatohepatitis | Hepagene (Shanghai) Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HPG1860 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04480697 ↗ |
| Modality | Small molecule | — CHEMBL6068610 ↗ |
| Route | Oral | “HPG1860 orally administered in healthy subjects” NCT04480697 ↗ |